BiotechTube

zodasiran Injection + Placebo

Phase 3Recruiting
3 views this week 0 watching⚡ Active📊Featured in Mid-Cap Catalyst Watch
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Homozygous Familial Hypercholesterolemia

Conditions

Homozygous Familial Hypercholesterolemia

Trial Timeline

Jun 17, 2025 → Aug 20, 2027

NCT ID
NCT07037771

About zodasiran Injection + Placebo

zodasiran Injection + Placebo is a phase 3 stage product being developed by Arrowhead Pharmaceuticals for Homozygous Familial Hypercholesterolemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07037771. Target conditions include Homozygous Familial Hypercholesterolemia.

What happened to similar drugs?

1 of 16 similar drugs in Homozygous Familial Hypercholesterolemia were approved

Approved (1) Terminated (0) Active (15)
✅evolocumabAmgenApproved
🔄Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
🔄Rosuvastatin 20mgAstraZenecaPhase 3
🔄Inclisiran + PlaceboNovartisPhase 3
🔄Inclisiran Sodium for injection + Placebo + PlacebosNovartisPhase 3
🔄InclisiranNovartisPhase 3
🔄Inclisiran + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07037771Phase 3Recruiting

Competing Products

20 competing products in Homozygous Familial Hypercholesterolemia

See all competitors
ProductCompanyStageHype Score
Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
40
Rosuvastatin 20mgAstraZenecaPhase 3
40
Inclisiran + PlaceboNovartisPhase 3
40
Inclisiran Sodium for injection + Placebo + PlacebosNovartisPhase 3
40
InclisiranNovartisPhase 3
44
INC280 + BuparlisibNovartisPhase 1/2
24
Inclisiran + PlaceboNovartisPhase 3
47
Evolocumab + PlaceboAmgenPhase 2/3
38
evolocumabAmgenApproved
43
MBX-8025 50 mg (Dose Escalation Period 1) + MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) + MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)Gilead SciencesPhase 2
35
IBI306 + IBI306Innovent BiologicsPhase 2/3
38
BMS-986504 + [14C]-BMS-986504Bristol Myers SquibbPhase 1
36
Lumacaftor Plus Ivacaftor Combination + Ivacaftor + PlaceboVertex PharmaceuticalsPhase 3
40
Placebo + Lumacaftor Plus Ivacaftor Combination + IvacaftorVertex PharmaceuticalsPhase 3
40
Lumacaftor Plus Ivacaftor Combination + IvacaftorVertex PharmaceuticalsPhase 3
40
Alirocumab + PlaceboSanofiPhase 3
40
AK102 + Statins + EzetimibeAkesoPhase 2
35
EvinacumabRegeneron PharmaceuticalsPhase 3
40
evinacumabRegeneron PharmaceuticalsPhase 3
40
REGN1500 250 mg SC/15 mg/kg IV/450 mg SCRegeneron PharmaceuticalsPhase 2
35